What is BioNTech?
BioNTech SE is a biotechnology company headquartered in Mainz, Germany, dedicated to developing and manufacturing patient-specific active immunotherapies for a range of diseases. The company's innovative approach focuses on personalized medicine, leveraging cutting-edge scientific research to create tailored treatments. BioNTech's strategic positioning in the market is further solidified by its significant backing, enabling it to advance its pipeline of novel therapeutic candidates and expand its operational capabilities.
How much funding has BioNTech raised?
BioNTech has raised a total of $1.3B across 6 funding rounds:
Series A
$270M
Series B
$325M
Other Financing Round
$55.7M
Multiple Rounds
$694.8M
Series A (2018): $270M with participation from Invus, Redmile Group, Struengmann Family Office, Janus Henderson Investors, and Fidelity Management & Research Company
Series B (2019): $325M led by BVCF Management, Jebsen Capital, MiraeAsset Financial Group, Fidelity Management & Research Company, Platinum Asset Management, Redmile Group, Struengmann Family Office, Steam Athena Capital, and Invus
Other Financing Round (2019): $55.7M supported by European Investment Bank
Debt (2020): $112.4M featuring European Investment Bank
Share Placement (2020): $139M backed by Temasek
Grant (2020): $443.3M with participation from Government of Germany
Key Investors in BioNTech
European Investment Bank
Established in 1958 and headquartered in Luxembourg, European Investment Bank (EIB) is the European Union's nonprofit long-term lending and finance institution.
Temasek
Founded in 1974, Temasek is a global investment company headquartered in Singapore. We are a generational investor, seeking to make a difference always with tomorrow in mind.
Invus
Invus Group is an investment firm specializing in financial advice, investment services, and consulting services. The company was founded in 1985 and is headquartered in New York City, New York.
What's next for BioNTech?
The substantial enterprise-level capital infusion and recent strategic investment signal BioNTech's robust trajectory and its critical role in advancing next-generation medical treatments. This financing is poised to accelerate the company's clinical trials, enhance its manufacturing capacity, and potentially expand its global reach. BioNTech's commitment to innovation in immunotherapy suggests a future focused on addressing unmet medical needs and solidifying its position as a leader in personalized medicine.
See full BioNTech company page
